Literature DB >> 1358442

Pharmacologic controversy of CNS stimulants in Gilles de la Tourette's syndrome.

M M Robertson1, V Eapen.   

Abstract

The controversy of the use of stimulants in Gilles de la Tourette's syndrome (GTS) can only be understood by examining the relationship between GTS and attention deficit-hyperactivity disorder (ADHD), because the relationship between the two disorders is complex, and stimulants are used in the one (ADHD) and may be contraindicated in the other (GTS). This relationship therefore has to be viewed from several perspectives, including clinical, genetic, neurobiochemical, neurophysiological, and treatment strategies, to highlight the complexities involved, and reasons for controversy. The present review will examine these relationships, and thus the evidence for and against the treatment of GTS with stimulants.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358442     DOI: 10.1097/00002826-199210000-00010

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  4 in total

Review 1.  Gilles de la Tourette syndrome: symptomatic treatment based on evidence.

Authors:  M M Robertson; J S Stern
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

2.  Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.

Authors:  Michael H Bloch; Kaitlyn E Panza; Angeli Landeros-Weisenberger; James F Leckman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-09       Impact factor: 8.829

Review 3.  Tourette's syndrome: are stimulants safe?

Authors:  Roger Kurlan
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

Review 4.  Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary.

Authors:  Mary M Robertson
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-02       Impact factor: 4.785

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.